{"nctId":"NCT01265394","briefTitle":"Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects","startDateStruct":{"date":"2010-12"},"conditions":["Healthy"],"count":218,"armGroups":[{"label":"(18F) Flutemetamol","type":"EXPERIMENTAL","interventionNames":["Drug: [18F] Flutemetamol"]}],"interventions":[{"name":"[18F] Flutemetamol","otherNames":["AH110690"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The subject age is 18 to 40 years.\n* The subject has no evidence of thinking or memory problems by medical history.\n* The subject has a normal MRI scan.\n* The subject's general health is adequate to comply with study procedures.\n* The subject is willing and able to participate in all study procedures.\n\nExclusion Criteria:\n\n* The subject has received any medical ionizing radiation exposure in the last 12 months (except planar x-ray or head CT).\n* The subject has a contraindication for (cannot undergo) MRI.\n* The subject has a history of head injury with loss of consciousness.\n* The subject has any significant medical, psychiatric or neurological condition that might be associated with brain pathology.\n* The subject has a family history of Alzheimer's Disease (AD); more than 1 first-degree relative.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show Amyloid","description":"The visual assessment of Flutemetamol PET image was performed by independent readers trained in the evaluation of PET brain amyloid imaging.\n\nThe measure would consisted of the number of brain scans with amyloid (abnormal reading) or without amyloid (normal reading).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Measurement of Amyloid Content in Different Parts of the Brain","description":"Is the computerized measurement of amyloid content in different parts of the brain.\n\nThe Standard Uptake Value Ratio (SUVR) is defined as an average of frontal, anterior cingulate, pariteal, lateral-temporal and posterior cingulate / precuneous uptake following administration of Flutemetamol F18 Injection.\n\nThe Standard Uptake Value Ratio is calculated for two regions of the brain, the Cerebullum and the Pons regions.\n\nThe Standard Uptake Value Ratio is calculated for two regions of the brain, the Cerebullum and the Pons regions. Both regions of the brain will provide the SUVR measurements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"0.097"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"0.036"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":181},"commonTop":["General Disorders and Administration Site Conditions","Vascular System Disorders","Vascular System Disorders-Flushing","Gastrointestinal disorders"]}}}